Atrium Therapeutics Receives FDA IND Clearance for RNA Therapeutic ATR 1072 to Treat PRKAG2 Syndrome, Advancing to Phase 1/2 Corventis Trial

July 26, 2026

Clival Database USA

Overview

Atrium Therapeutics announced FDA Investigational New Drug (IND) clearance for ATR 1072, an RNA therapeutic in development for the rare PRKAG2 syndrome. This clearance allows the company to proceed with the Phase 1/2 Corventis clinical trial, which will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATR 1072. This marks a significant milestone, offering new hope for PRKAG2 syndrome patients with limited treatment options.

In Depth

Key Findings

Atrium Therapeutics has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for ATR 1072, an innovative RNA therapeutic designed to treat PRKAG2 syndrome, a rare genetic disorder. This clearance enables the company to advance the clinical development of ATR 1072 into a Phase 1/2 clinical trial known as Corventis.

Technical / Clinical Details

ATR 1072 is an RNA therapeutic engineered to directly target the genetic mutation underlying PRKAG2 syndrome. PRKAG2 syndrome is a rare inherited disorder affecting the heart’s electrical conduction system and muscle function, leading to conditions such as cardiac hypertrophy and arrhythmias, which can result in severe cardiac complications. Currently, specific treatments for this disease are limited, with symptomatic management being the primary approach. With IND clearance, Atrium Therapeutics will initiate the ‘Corventis’ Phase 1/2 clinical trial to evaluate the drug’s safety and tolerability in humans. Additionally, its pharmacokinetics (absorption, distribution, metabolism, and excretion within the body) and pharmacodynamics (mechanism of action and effects on the body), along with preliminary efficacy against the disease, will be assessed. This trial is expected to position ATR 1072 as one of the first potential therapies to directly intervene in the pathophysiology of PRKAG2 syndrome.

Background & Context

RNA therapeutics are rapidly advancing as a next-generation drug modality that treats diseases by specifically targeting and controlling protein expression. They hold particular promise as a solution for previously untreatable rare and genetic diseases. Genetic heart diseases like PRKAG2 syndrome represent areas of high unmet medical need, where research and development have been challenging due to small patient populations. The FDA’s IND clearance indicates that ATR 1072’s non-clinical data support a sufficient safety profile and scientific rationale for initial human testing, marking a significant advancement in rare disease drug development.

Strategic Significance & Outlook

The initiation of the Phase 1/2 Corventis clinical trial for ATR 1072 offers significant hope for patients and families affected by PRKAG2 syndrome. If this trial is successful and the drug proves safe and effective, it could fundamentally change the treatment paradigm for PRKAG2 syndrome. Atrium Therapeutics aims to establish leadership in this rare disease area and potentially apply RNA therapeutics to other cardiac conditions with similar unmet medical needs. Investors and researchers will closely monitor these early clinical data, evaluating the potential of the RNA therapeutic platform and new opportunities in the rare disease market.

Source: https://clival.com/news/us-fda-clears-atrium-therapeutics-ind-application-for-atr-1072-to-treat-of-prkag2-syndrome

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.